June 27 (Reuters) - Celltrion Inc:
* WINS SALES APPROVAL RECOMMENDATION FOR ITS CT-P16 FROM EUROPEAN MEDICINES AGENCY'S COMMITTEE Further company coverage: (Reporting by ByungwookKim Kim)
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,94,400 KRW | +2.86% | +2.86% | -3.52% |
24/04 | Market Share of Celltrion’s Remsima Rises to 74% in Europe | MT |
17/04 | Celltrion, Inc. announces an Equity Buyback for 436,047 shares. | CI |
June 27 (Reuters) - Celltrion Inc:
* WINS SALES APPROVAL RECOMMENDATION FOR ITS CT-P16 FROM EUROPEAN MEDICINES AGENCY'S COMMITTEE Further company coverage: (Reporting by ByungwookKim Kim)
1st Jan change | Capi. | |
---|---|---|
-3.52% | 28.87B | |
+21.74% | 46.81B | |
-0.97% | 41.37B | |
+47.07% | 41.29B | |
+11.12% | 26.06B | |
-19.37% | 19.13B | |
+31.18% | 12.39B | |
-0.04% | 12.08B | |
+0.39% | 11.96B | |
+21.07% | 11.56B |